FDA Fast Track for Sangamo's Experimental Pain Drug in Rare Neuropathy Trial
FDA Fast Track for Sangamo's Experimental Pain Drug in Rare Neuropathy Trial
FDA Fast Track for Sangamo's Experimental Pain Drug in Rare Neuropathy Trial
Sangamo Therapeutics has secured FDA Fast Track Designation for ST-503, an experimental drug aimed at treating chronic neuropathic pain in small fibre neuropathy (SFN). The condition, which affects around 53 in every 100,000 people in the U.S., currently lacks effective long-term treatments. This designation could speed up the drug's development and review process for patients with severe, hard-to-treat pain.
ST-503 is an investigational epigenetic regulator designed to address the unmet need for chronic neuropathic pain relief. Sangamo Therapeutics, a company specialising in genomic medicine, is focusing on turning cutting-edge science into treatments for serious neurological diseases. Their latest effort, the STAND study, will test ST-503 in a Phase 1/2 trial.
The STAND study is structured as a multicentre, double-blind, and randomised trial. It will use a sham-controlled dose escalation approach to evaluate the drug's safety, tolerability, and early signs of effectiveness. While exact patient numbers and key study locations remain undisclosed, the company is now preparing to administer the first dose to participants.
Fast Track Designation from the FDA helps accelerate the development of therapies for serious or life-threatening conditions. This status may allow ST-503 to reach patients faster if clinical results prove promising.
The FDA's Fast Track Designation highlights the urgency for new SFN treatments, where options are currently limited. Sangamo's upcoming STAND study will determine whether ST-503 can safely and effectively address intractable pain in patients. If successful, the drug could offer a much-needed solution for those suffering from this debilitating condition.
B.C. expands deer hunt to combat chronic wasting disease outbreak
A deadly outbreak pushes B.C. to act—hunters get extra permits to thin deer herds. Can this stop the disease from spreading further?
India's fast-food boom clashes with rising obesity and diabetes crises
Urban lifestyles drive record fast-food demand, but the cost is steep: one in four adults now battles heart disease. Will stricter rules turn the tide?
SHIP study launches new health exams for 1,000 long-term participants
Decades of health insights unfold as SHIP's latest phase dives into ageing and disease. How will this data reshape public health research?
Silicosis Crisis Hits US Stone Workers as Industry Seeks Legal Shield
A grandfather and son both stricken by silicosis expose the hidden toll of quartz countertops. Now, the $30B industry wants Congress to block lawsuits—leaving families fighting for justice.